ClinicalTrials.gg
RecruitingNCT06306443Updated Jun 4, 2026

Buprenorphine for Individuals in Jail

A Phase 3 interventional study of extended-release buprenorphine (XR-B) in Opioid Use Disorder, sponsored by Friends Research Institute, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Friends Research Institute, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc. — 4 open to participants now, 7 under way, 3 of them phase 3. Opioid-Related Disorders · Friends Research Institute, Inc..

Planned enrollment
7th of 20
240 · median 235
Started
2025
with 4 others
Phase 3
4 of 20
1 open now
Registered
15th of 20
by date

Among the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., this one is the 7th largest by planned enrollment, is one of 5 that started in 2025, is one of 4 in phase 3, and was the 15th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Opioid-Related Disorders by Friends Research Institute, Inc., or all of them as a file.
02

Study summary

This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed by 6-months of post-release buprenorphine treatment, a 7-month safety visit, and a final long-term follow-up at 12-months.

Read the detailed description

This study is an open label randomized controlled trial of extended-release buprenorphine (BRIXADI, XR-B) vs. sublingual buprenorphine (SL-B) in a large metropolitan jail. An open-label design will randomly assign 240 adults with moderate-to-severe OUDs who are soon-to-be-released from jail to either XR-B (n=120) or SL-B (n=120) treatment in jail followed by 6-months of post-release buprenorphine treatment, a 7-month safety visit, and a final long-term follow-up at 12-months.

Aim 1. Compare the effectiveness of XR-B vs. SL-B Aim 2. To calculate the cost to the state and/or jail/city health system of implementing XR-B and SL-B, and determine the relative value, including the costs associated with the interventions in the community, from a county and state-policymaker and societal perspective.

Aim 3. Explore barriers and facilitators to XR-B versus SL-B implementation in jail: (1) dose induction; (2) diversion and procedures for reducing diversion; (3) continuity of care after release or transfer to another facility; (4) staffing (both custody and medical) needs for daily versus XR-B buprenorphine dosing; and (5) patient preference for XR-B versus SL-B.

Primary Outcome. (a) illicit opioid use (i. urine toxicology; ii. self-reported days of opioid use using Timeline Followback; and iii. time to opioid relapse).

Secondary Outcomes. (b) retention in buprenorphine treatment (i. days receiving buprenorphine and ii. time to treatment dropout); (c) other illicit substance use (i. urine toxicology; ii. self-reported days of illicit substance use using Timeline Followback; (d) overdose events (non-fatal and fatal); (e) quality of life (i. physical health; ii. mental health); (f) HIV risk behaviors (i. sexual risk behavior; ii. needle use or sharing); and (g) criminal activity (i. crime days; ii. re-arrest; iii. technical violations; iv. re-incarceration).

Costs. (a) cost to the correctional system; (b) costs associated with community intervention

03

Conditions studied

  • Opioid Use Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female inmates at participating jail who are eligible for release within 120 days (sentenced and/or pretrial [note: individuals who might be sentenced to state/federal prison will be excluded]); Those individuals who are pre-trial and/or sentenced who are completing their sentence in the community (probation, parole, home detention, electronic monitoring, drug or other treatment court [or equivalent]) will be eligible to participate;
  • History of opioid use disorder (meeting criteria of moderate or severe opioid use disorder at the time of incarceration; individuals not meeting the opioid-disorder criterion will be eligible if they were treated in an opioid agonist treatment program during the year before incarceration);
  • Suitability for XR-B and/or SL-B treatment as determined by medical evaluation;
  • Willingness to enroll in XR-B or SL-B treatment in jail and continue in the community;
  • Planning to live in Baltimore City or the Baltimore Region;

Exclusion criteria

Exclusion Criteria:

  • Liver function test levels greater than 5 times normal (if we are unable to obtain labs, a determination by the study physician will be made to allow inclusion);
  • Active medical illness that may make participation hazardous (e.g., unstable diabetes, heart disease; moderate to severe renal impairment; adequately treated medical conditions are acceptable);
  • Conditions or medications that may predispose to prolongation (personal or family history of long QT syndrome, hypokalemia, medications that prolong QTc interval, e.g., macrolide antibiotics, azole antifungal compounds, anti-arrythmics, antipsychotics and antidepressant);
  • Untreated psychiatric disorder that may make participation hazardous (e.g., untreated psychosis, bipolar disorder with mania; adequately treated psychiatric disorders and appropriate psychotropic medications will be allowed);
  • History of allergic reaction to buprenorphine;
  • Suicidal ideation (within the past 6 months);
  • Inability to pass a study enrollment quiz; and
  • Currently receiving non-buprenorphine MOUD in jail (methadone, naltrexone).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    extended-release buprenorphine (XR-B)

    Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone. If they tolerate sl buprenorphine, on day 4 they will be administered an 8 mg dose of BRIXADI on day 5 (if they do not tolerate sl buprenorphine/naloxone we will extend sl dosing). During week two of dosing, they will receive 16 mg dose of BRIXADI will be given, based on the participant's response to the previous dose. During week three of dosing, they will receive a 24 mg dose of BRIXADI. During week four they will be administered a monthly dose of 64mg, 96mg, or 128mg. In all cases, the dose selected will be based on their response to the previous weeks' dose. We will endeavor to get you on the 96 mg or 128 mg monthly dose as there is a lack of opioid blockade data for the 64 mg monthly dose.

    Drug: extended-release buprenorphine (XR-B)

  • Active comparator
    sublingual buprenorphine (SL-B)

    Participants will receive sublingual (sl; taken under the tongue) buprenorphine/naloxone doses of 2 mg for two days followed by 4mg for 2 days. The speed of induction will be based on their response to sl buprenorphine/naloxone.

    Drug: extended-release buprenorphine (XR-B)

Interventions

  • Drugextended-release buprenorphine (XR-B)

    buprenorphine

    Also known as: sublingual buprenorphine (SL-B)

06

What researchers measure

Primary outcomes

  1. urine toxicology

    positive urine drug screen for opioids

    Time frame: 12-months

  2. days of opioid use

    Number of days since last assessment

    Time frame: 12-months

  3. time to opioid relapse

    days from release from jail to first relapse event

    Time frame: 12-months

Secondary outcomes

  1. retention in buprenorphine treatment

    days receiving buprenorphine

    Time frame: 6-months

  2. urine toxicology for other illicit substance use

    positive urine drug screen

    Time frame: 12-months

  3. days of illicit substance use

    number of days since last assessment

    Time frame: 12-months

  4. overdose events

    fatal and non-fatal overdose events

    Time frame: 12-months

  5. PROMIS Patient-Reported Outcomes Measurement Information System - physical health

    Global physical health score

    Time frame: 12-months

  6. PROMIS Patient-Reported Outcomes Measurement Information System - mental health

    Global mental health score

    Time frame: 12-months

  7. HIV risk behaviors (Risk Assessment Battery, RAB) - sex risk score

    sexual risk behavior; Scored 0-18 (higher risk)

    Time frame: 12-months

  8. HIV risk behaviors (Risk Assessment Battery, RAB) needle use or sharing score

    needle use or sharing; Scored 0-22 (higher risk)

    Time frame: 12-months

  9. criminal activity

    i. crime days; ii. re-arrest; iii. technical violations; iv. re-incarceration

    Time frame: 12-months

07

Study locations

2 of 2 sites recruiting
  • Friends Research Institute
    Baltimore, Maryland 21201, United States
    Recruiting
  • Baltimore Central Booking & Intake Center
    Baltimore, Maryland 21202, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Working on a plan.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2029, 42 months after the start.

Of 31 phase 3 interventional studies under Opioid-Related Disorders, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 42 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 12, 2024
StartActual
Jun 20, 2025
Primary completionEst.
Jan 1, 2029
CompletionEst.
Apr 30, 2029
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06306443
Lead sponsor
Friends Research Institute, Inc.
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Jun 20, 2025
Primary completion
Jan 1, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Jun 4, 2026

Study contacts

Michael Gordon, DPA
Contact
mgordon@friendsresearch.org
4108373977 ext. 251
Thomas R Blue, PhD
Contact
tblue@friendsresearch.org
4108373977

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion